Nasdaq · Healthcare
Axsome Therapeutics, Inc. (AXSM)
As-reported financials and recent SEC filings for Axsome Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$638.5M
Net income
$-183.2M
Net margin
-28.7%
Diluted EPS
$-3.68
ROE
-207.5%
P/E (TTM)
—
Market cap
$12.44B
Debt / equity
1.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | — |
| Gross profit | — | — | — | $44.8M | — |
| Operating income | $-166.8M | $-280.6M | $-231.8M | $-179.8M | $-124.7M |
| Net income | $-183.2M | $-287.2M | $-239.2M | $-187.1M | $-130.4M |
| Diluted EPS | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-11
View on EDGAR →42026-06-11
View on EDGAR →1442026-06-10
View on EDGAR →1442026-06-10
View on EDGAR →1442026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →Go deeper on AXSM
Search Axsome Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.